Tag: Gilead sciences

In July 2003, the U.S. Food and Drug Administration (FDA) approved the once-daily HIV medication **Emtriva**. The biopharmaceutical company Gilead Sciences, Inc. holds the trademark and is responsible for the manufacturing and marketing of this essential antiretroviral drug.

Originally developed in 2009 by Gilead Sciences, the antiviral drug remdesivir was initially intended to combat hepatitis C and respiratory syncytial virus (RSV) before being repurposed for its eventual, more famous applications. The history of remdesivir is a remarkable narrative of scientific repurposing, highlighting how a broad-spectrum antiviral candidate evolved from treating one family of viruses to becoming a key tool in global pandemic responses, including both Ebola and COVID-19.

Primary biliary cholangitis (PBC) is a rare, chronic inflammatory liver disease that can lead to debilitating symptoms [1.2.3]. A key treatment option is Livdelzi, but **what is the generic name for Livdelzi?** The generic name is **seladelpar** [1.2.2].

In October 2020, Veklury (remdesivir) became the first FDA-approved treatment for COVID-19. If you've been wondering, "what is the new name for remdesivir?", the answer lies in understanding the distinction between a drug's generic and brand name. The generic name for this antiviral medication is remdesivir, while Veklury is its proprietary brand name, created and marketed by Gilead Sciences.

Chronic hepatitis delta (HDV) is widely regarded as the most severe form of viral hepatitis, affecting millions worldwide. For adults with this condition and compensated liver disease, bulevirtide is used for chronic HDV infection, offering a targeted therapeutic option where few effective treatments previously existed.

Pulmonary arterial hypertension (PAH) is a chronic, progressive disease characterized by elevated blood pressure in the arteries of the lungs. Approved by the FDA in 2007, LETAIRIS, also known by its active ingredient ambrisentan, offers a targeted approach to managing this serious condition. But **what does LETAIRIS do** to alleviate the symptoms and slow the progression of PAH?

Lenacapavir's breakthrough development as a long-acting HIV treatment and prevention medication was the result of a decades-long, collaborative effort between the National Institutes of Health (NIH) and pharmaceutical company Gilead Sciences, not a single individual. So, who invented lenacapavir? The answer lies in this partnership that built on foundational scientific research.

Following its FDA approval in June 2025, Yeztugo (lenacapavir) became the first and only twice-yearly injectable option for HIV pre-exposure prophylaxis (PrEP) in the United States. For those asking, 'Is Yeztugo available?', the answer is yes in the United States, representing a significant advancement in HIV prevention by simplifying the dosing schedule and addressing adherence barriers.

On December 22, 2022, the FDA approved Sunlenca (lenacapavir), a groundbreaking, long-acting medication for heavily treatment-experienced adults living with multidrug-resistant HIV-1. This first-in-class capsid inhibitor offers a twice-yearly subcutaneous injection, revolutionizing treatment options for those with limited alternatives.